Company profile: Day One Bio
1.1 - Company Overview
Company description
- Provider of targeted therapies for life-threatening diseases, including OJEMDA (tovorafenib), FDA-approved for children with BRAF-altered relapsed or progressive pediatric low-grade glioma; advancing investigational MAPK-pathway inhibitors tovorafenib and pimasertib and conducting FIREFLY-1/2 and FIRELIGHT-1 trials in brain and solid tumors with MAPK pathway aberrations.
Products and services
- OJEMDA (tovorafenib): FDA-approved therapy for children with BRAF-altered, relapsed or progressive pediatric low-grade glioma (pLGG)
- FIREFLY-2 Clinical Trial: Phase 3 trial comparing tovorafenib against standard chemotherapy in pediatric low-grade glioma requiring systemic therapy
- Tovorafenib: Investigational therapy targeting the MAPK signaling pathway, in trials for brain tumors and solid tumors with MAPK pathway aberrations
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Day One Bio
Salmedix
HQ: United States
Website
- Description: Provider of oncology drug development focused on hematologic malignancies (blood cancers). Primary product SDX-105 is marketed by healthcare professionals in Germany for several types of blood cancers; conducts Phase II clinical trials for SDX-105 in the U.S. and Canada.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Salmedix company profile →
G1 Therapeutics
HQ: United States
Website
- Description: Provider of next-generation anticancer therapies, including trilaciclib, a transient intravenous CDK4/6 inhibitor administered before chemotherapy to protect bone marrow and enhance immune function; lerociclib, an oral CDK4/6 inhibitor for use with other therapies; and rintodestrant (G1T48), an oral SERD for estrogen receptor–positive breast cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full G1 Therapeutics company profile →
OncoMed
HQ: United States
Website
- Description: Provider of biotechnology therapeutics developing monoclonal antibodies that target pathways critical to tumor-initiating (cancer stem) cells to improve cancer treatment. Pipeline includes etigilimab with nivolumab for advanced solid tumors, navicixizumab for platinum-resistant ovarian cancer (with OncXerna), setrusumab for OI, alvelestat for AATD-LD, acumapimod for AECOPD, and leflutrozole (with ReproNovo).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OncoMed company profile →
RedPath Integrated Pathology
HQ: United States
Website
- Description: Provider of reference laboratory services and oncology case support, offering PathFinderTG, a testing platform for resolving diagnoses from the original pathology specimen, serving pathologists, clinicians, and patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full RedPath Integrated Pathology company profile →
Ultivue
HQ: United States
Website
- Description: Provider of tissue imaging and multiplex biomarker assay solutions for precision medicine research, including InSituPlex DNA-barcoded antibody technology, custom assay development, pre-optimized ready-to-use multiplex staining kits, specialized AI tools and full lifecycle image analysis for multiplex immunofluorescence, and OmniVUE customizable biomarker panel design kits.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ultivue company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Day One Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Day One Bio
2.2 - Growth funds investing in similar companies to Day One Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Day One Bio
4.2 - Public trading comparable groups for Day One Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →